Aaren Kettelhut1, Emily Bowman1, Nicholas T Funderburg2. 1. Division of Medical Laboratory Science, School of Health and Rehabilitation Sciences, Ohio State University College of Medicine, Columbus, OH, USA. 2. Division of Medical Laboratory Science, School of Health and Rehabilitation Sciences, Ohio State University College of Medicine, Columbus, OH, USA. Nicholas.Funderburg@osumc.edu.
Abstract
PURPOSE OF REVIEW: In this review, we will discuss treatment interventions targeting drivers of immune activation and chronic inflammation in PWH. RECENT FINDINGS: Potential treatment strategies to prevent the progression of comorbidities in PWH have been identified. These studies include, among others, the use of statins to modulate lipid alterations and subsequent innate immune receptor activation, probiotics to restore healthy gut microbiota and reduce microbial translocation, hydroxychloroquine to reduce immune activation by altering Toll-like receptors function and expression, and canakinumab to block the action of a major pro-inflammatory cytokine IL-1β. Although many of the treatment strategies discussed here show promise, due to the complex nature of chronic inflammation and comorbidities in PWH, larger clinical studies are needed to understand and target the prominent drivers and inflammatory cascades underlying these end-organ diseases.
PURPOSE OF REVIEW: In this review, we will discuss treatment interventions targeting drivers of immune activation and chronic inflammation in PWH. RECENT FINDINGS: Potential treatment strategies to prevent the progression of comorbidities in PWH have been identified. These studies include, among others, the use of statins to modulate lipid alterations and subsequent innate immune receptor activation, probiotics to restore healthy gut microbiota and reduce microbial translocation, hydroxychloroquine to reduce immune activation by altering Toll-like receptors function and expression, and canakinumab to block the action of a major pro-inflammatory cytokine IL-1β. Although many of the treatment strategies discussed here show promise, due to the complex nature of chronic inflammation and comorbidities in PWH, larger clinical studies are needed to understand and target the prominent drivers and inflammatory cascades underlying these end-organ diseases.
Authors: Aaren Kettelhut; Emily Bowman; Janelle Gabriel; Brittany Hand; Namal P M Liyanage; Manjusha Kulkarni; Frances Avila-Soto; Jordan E Lake; Nicholas T Funderburg Journal: Front Immunol Date: 2022-06-03 Impact factor: 8.786
Authors: Mingdi Li; Iris Wenyu Zhou; Janine Trevillyan; Anna C Hearps; Anthony Lin Zhang; Anthony Jaworowski Journal: Front Cardiovasc Med Date: 2022-08-16